Compare ARK Genomic Revolution ETF (ARKG) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs iShares Core High Dividend ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while iShares Core High Dividend ETF trades at $27.87. Which is the better fit depends on your goals.
| ARKG | HDV | |
|---|---|---|
Sector | Sector/Thematic | — |
52-Week High | $43.57 | $28.09 |
52-Week Low | $23.09 | $23.63 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
HDV (iShares Core High Dividend ETF) trades at $27.70, up 0.44% with a bullish technical signal from moving averages. The ETF focuses on high-quality dividend stocks with a 3.0% yield and has delivered strong 5-year total returns. Recent news highlights HDV's competitive expense ratio, defensive sector allocation, and lower volatility compared to the S&P 500.
HDV presents a compelling income opportunity with quality screening and defensive positioning, though its 21.56% energy allocation introduces sector-specific volatility. The ETF's low beta of 0.52 provides stability, making it suitable for risk-averse investors seeking dividend income with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
